Pharmacogenetic Testing in the Outpatient Setting in Switzerland: A Descriptive Study Using Swiss Claims Data
Open Access
- 20 February 2025
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 48 (6) , 689-696
Abstract
Background In Switzerland, consumers are exposed to drugs with pharmacogenetic (PGx) recommendations in 78% of cases. Pre-emptive PGx testing for seven drugs (abacavir, carbamazepine, 6-mercaptopurine, azathioprine, 5-fluorouracil, capecitabine, and irinotecan) has been covered by basic health insurance since 2017. PGx testing for other drugs is only covered if it is reactive and prescribed by a clinical pharmacologist. No data are yet available on the implementation of PGx testing in the outpatient setting. Aim The objective of this study was to determine the prevalence of ambulatory PGx testing in the Swiss population, to characterize PGx-tested individuals, and to identify the most commonly used drugs before and after PGx testing. Methods We assessed the prevalence of PGx testing in Switzerland and characterized individuals who underwent PGx testing between 2017 and 2021 using claims data from a large health insurance company. Results Of 894,748 individuals registered for the entire study period, only 817 (0.09%) underwent PGx testing. Those who underwent PGx testing were more frequently female and claimed more drugs and PGx drugs than those who did not undergo PGx testing. The drugs used before and after PGx testing differed, and fewer drugs with reimbursement for pre-emptive PGx testing were included before PGx testing. Conclusion In Switzerland, personalized pharmacotherapy has the potential to be improved, as only 0.09% of the studied population underwent PGx testing, despite 77.4% claiming PGx drugs.Keywords
Funding Information
- University of Basel
This publication has 35 references indexed in Scilit:
- A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation studyThe Lancet, 2023
- A systematic review of pharmacogenetic testing in primary care: Attitudes of patients, general practitioners, and pharmacistsResearch in Social and Administrative Pharmacy, 2022
- Implementation of preemptive DNA sequence–based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K StudyGenetics in Medicine, 2022
- The impact of the COVID-19 pandemic on the continuity of care for at-risk patients in Swiss primary care settings: A mixed-methods studySocial Science & Medicine, 2022
- An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized MedicineClinical Pharmacology & Therapeutics, 2021
- Pharmacogenetics at Scale: An Analysis of the UK BiobankClinical Pharmacology & Therapeutics, 2020
- Coverage rates and timeliness of nationally recommended vaccinations in Swiss preschool children: A descriptive analysis using claims dataVaccine, 2020
- Genetic testing for prevention of severe drug-induced skin rashCochrane Database of Systematic Reviews, 2019
- Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic ReviewClinical Pharmacology & Therapeutics, 2018
- Preemptive Pharmacogenomic Testing for Precision MedicineThe Journal of Molecular Diagnostics, 2016